GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Valganciclovir Hydrochloride

Company
City of Hope Medical Center
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
20 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

20 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Valganciclovir Hydrochloride and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01419561

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

    Not yet reported National Cancer Institute (NCI) 140 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
    View official trial listing →
  • Recruiting NCT NCT03511118

    Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    Duke University 1600 participants Est. completion 2028-07-31 22 sites
    Other conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
    View official trial listing →
  • Recruiting NCT NCT04278404

    Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    Duke University 5000 participants Est. completion 2026-12 52 sites
    Heart failure Other conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
    View official trial listing →
  • Recruiting NCT NCT04439916

    Breakthrough CMV Lung Transplant -Multicentre

    University of Alberta 40 participants Est. completion 2027-12 1 site
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Recruiting NCT NCT05564598

    CMV CTLs in Neonates With CMV Infection

    Not yet reported New York Medical College 23 participants Est. completion 2028-10-31 4 sites Stand-alone
    Other conditions: Congenital Cytomegaloviral (CMV) Disease
    View official trial listing →
  • Recruiting NCT NCT05708508

    Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients

    Not yet reported University Hospital, Rouen 144 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Kidney Transplant Infection
    View official trial listing →
  • Recruiting NCT NCT05708755

    CMV Immunity Monitoring in Lung Transplant Recipients

    Not yet reported NYU Langone Health 50 participants Est. completion 2028-05 1 site Stand-alone
    Other conditions: Lung Transplant; Complications
    View official trial listing →
  • Recruiting NCT NCT06102525

    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

    Not yet reported, Not yet reported Rznomics, Inc. 43 participants Est. completion 2029-05 6 sites Stand-alone
    Other conditions: Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT06334497

    Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

    Not yet reported Assistance Publique - Hôpitaux de Paris 80 participants Est. completion 2027-11 5 sites Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Recruiting NCT NCT06555432

    A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

    Takeda 168 participants Est. completion 2028-10-01 1 site
    Other conditions: Cytomegalovirus (CMV)
    View official trial listing →
  • Recruiting NCT NCT06695026

    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

    Not yet reported, Not yet reported Rznomics, Inc. 45 participants Est. completion 2027-10 9 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT06798909

    Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

    Not yet reported University of California, San Francisco 360 participants Est. completion 2031-05-31 8 sites Stand-alone
    Other conditions: Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
    View official trial listing →
  • Recruiting NCT NCT06853184

    Study Evaluating the Efficacy and Safety of Artesunate

    Not yet reported Amivas Inc. 90 participants Est. completion 2028-06-30 4 sites Stand-alone
    Other conditions: CMV Infection
    View official trial listing →
  • Recruiting NCT NCT06958796

    Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

    Not yet reported Camille N. Kotton, MD 80 participants Est. completion 2028-05-31 2 sites
    Other conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
    View official trial listing →
  • Recruiting NCT NCT07079735

    Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

    Not yet reported, Not yet reported Columbia University 150 participants Est. completion 2029-01-17 2 sites
    Other conditions: CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
    View official trial listing →
  • Recruiting NCT NCT07235683

    Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients

    Not yet reported University Health Network, Toronto 40 participants Est. completion 2027-08 1 site Stand-alone
    Other conditions: CMV, Lung Transplant Recipient
    View official trial listing →
  • Recruiting NCT NCT07266467

    Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 290 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Kidney Transplant
    View official trial listing →
  • Recruiting NCT NCT07294547

    Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

    Not yet reported National Taiwan University Hospital 80 participants Est. completion 2030-12 1 site
    Other conditions: Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
    View official trial listing →
  • Recruiting NCT NCT07383649

    Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

    Not yet reported The Methodist Hospital Research Institute 28 participants Est. completion 2030-05 1 site Stand-alone
    Other conditions: Brain Cancer Metastatic, CMV Viremia
    View official trial listing →
  • Recruiting NCT NCT07688759

    CMV-CMI in csCMVi After HSCT

    The First Affiliated Hospital of Soochow University 40 participants Est. completion 2028-08-31 1 site
    Other conditions: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
    View official trial listing →
  • Completed NCT NCT00002222

    A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

    Not yet reported Hoffmann-La Roche 200 participants 1 site
    Other conditions: Cytomegalovirus Retinitis, HIV Infections
    View official trial listing →
  • Completed NCT NCT00002377

    A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

    Not yet reported Hoffmann-La Roche Est. completion 2002-12 19 sites
    Other conditions: Cytomegalovirus Retinitis, HIV Infections
    View official trial listing →
  • Completed NCT NCT00006145

    Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 350 participants Est. completion 2006-02 57 sites
    Other conditions: Cytomegalovirus Infections, HIV Infections
    View official trial listing →
  • Completed NCT NCT00016068

    Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

    Not yet reported Fred Hutchinson Cancer Center 184 participants Est. completion 2007-09 7 sites
    Other conditions: Infection
    View official trial listing →
  • Status unknown NCT NCT00017784

    Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

    Not yet reported Hoffmann-La Roche 500 participants 9 sites
    Other conditions: Cytomegalovirus Retinitis, HIV Infections
    View official trial listing →
  • Completed NCT NCT00031434

    Valganciclovir in Congenital CMV Infants

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 24 participants Est. completion 2007-07 21 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00034385

    Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

    Not yet reported National Institutes of Health Clinical Center (CC) 12 participants Est. completion 2009-10-30 1 site
    Other conditions: Kidney Trasplant
    View official trial listing →
  • Completed NCT NCT00078559

    Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

    Not yet reported, Not yet reported University of Wisconsin, Madison 10 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Kidney Transplantation, Kidney Disease
    View official trial listing →
  • Completed NCT NCT00090766

    A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

    Not yet reported, Not yet reported Hoffmann-La Roche 63 participants Est. completion 2005-05 17 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Active, not recruiting NCT NCT00092222

    Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

    Not yet reported National Cancer Institute (NCI) 75 participants Est. completion 2028-10-01 1 site
    Other conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
    View official trial listing →
  • Completed NCT NCT00096538

    Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma

    Not yet reported Memorial Sloan Kettering Cancer Center 6 participants Est. completion 2008-02 3 sites Stand-alone
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT00141037

    Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 130 participants Est. completion 2010-11 12 sites Stand-alone
    Other conditions: Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
    View official trial listing →
  • Completed NCT NCT00189150

    Pharmacokinetics of Mmf and Valganciclovir

    Not yet reported University of Michigan 16 participants Est. completion 2007-08 1 site
    Other conditions: Kidney Transplant Recipient, Heart Transplant Recipient
    View official trial listing →
  • Completed NCT NCT00194467

    Suppression of Oral HHV8 Shedding With Valganciclovir

    Not yet reported University of Washington 32 participants Est. completion 2005-03 1 site Stand-alone
    Other conditions: Human Herpesvirus 8
    View official trial listing →
  • Completed NCT NCT00198224

    Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

    Not yet reported Indiana University 50 participants Est. completion 2005-05 2 sites
    Other conditions: Renal Failure
    View official trial listing →
  • Completed NCT NCT00217503

    Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

    Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2007-06 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00225394

    Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients

    University of Massachusetts, Worcester 100 participants Est. completion 2006-07 4 sites
    Other conditions: CMV Disease, Viral Resistance, Rejection, Death
    View official trial listing →
  • Completed NCT NCT00227370

    Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

    Not yet reported Duke University 136 participants Est. completion 2008-12 1 site
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Terminated NCT NCT00237653

    MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus

    Not yet reported University Hospital, Grenoble 40 participants Est. completion 2007-12 1 site
    Other conditions: Cytomegalovirus Infections, Inflammatory Bowel Diseases
    View official trial listing →
  • Terminated NCT NCT00241345

    Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

    Not yet reported Washington University School of Medicine 39 participants Est. completion 2007-12 1 site Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00264290

    Valganciclovir to Reduce T Cell Activation in HIV Infection

    Not yet reported University of California, San Francisco 30 participants Est. completion 2008-11 1 site Stand-alone
    Other conditions: HIV Infections, Cytomegalovirus Infections
    View official trial listing →
  • Terminated NCT NCT00275314

    WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

    Not yet reported University of Pittsburgh 5 participants Est. completion 2006-04 1 site
    Other conditions: Kidney Transplant
    View official trial listing →
  • Completed NCT NCT00275665

    The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

    Not yet reported Mayo Clinic 20 participants Est. completion 2007-07 1 site
    Other conditions: Bone Marrow Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT00294515

    IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

    Not yet reported Hoffmann-La Roche 326 participants Est. completion 2009-08-31 80 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00330018

    Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)

    Not yet reported Hadassah Medical Organization 40 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Bone Marrow Transplantation, Cytomegalovirus
    View official trial listing →
  • Withdrawn NCT NCT00361933

    Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

    Not yet reported University of Washington Est. completion 2009-05 Stand-alone
    Other conditions: Giant Lymph Node Hyperplasia
    View official trial listing →
  • Status unknown NCT NCT00364052

    Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

    Oregon Health and Science University 200 participants Est. completion 2007-01
    Other conditions: Liver Transplantation
    View official trial listing →
  • Completed NCT NCT00372229

    A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

    Not yet reported Hoffmann-La Roche 299 participants Est. completion 2015-10 24 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00374686

    Study of Prophylactic Vs Preemptive Valganciclovir

    Not yet reported Washington University School of Medicine 120 participants Est. completion 2005-09 1 site
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT00377741

    A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

    Not yet reported Hoffmann-La Roche 31 participants Est. completion 2006-06 5 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00386412

    TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

    Not yet reported PETHEMA Foundation 132 participants Est. completion 2009-09 8 sites
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Withdrawn NCT NCT00387530

    Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

    Not yet reported University of California, San Diego Est. completion 2008-01 1 site
    Other conditions: Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
    View official trial listing →
  • Completed NCT NCT00400322

    Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

    Not yet reported Karolinska Institutet 42 participants Est. completion 2008-06 3 sites
    Other conditions: Glioblastoma Multiforme, Cytomegalovirus Infection
    View official trial listing →
  • Terminated NCT NCT00415454

    Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

    Not yet reported Henry Ford Health System 8 participants 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00431353

    VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

    Not yet reported Hoffmann-La Roche 325 participants Est. completion 2008-08 50 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT00466817

    Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 109 participants Est. completion 2013-06 48 sites Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT00478465

    Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

    Not yet reported, Not yet reported Stanford University 30 participants Est. completion 2007-08 1 site
    Other conditions: Chronic Fatigue Syndrome
    View official trial listing →
  • Completed NCT NCT00562770

    Oral Valganciclovir Versus Valacyclovir

    Not yet reported M.D. Anderson Cancer Center 46 participants Est. completion 2006-07 1 site
    Other conditions: Chronic Lymphocytic Leukemia, Leukemia
    View official trial listing →
  • Completed NCT NCT00583492

    Randomized Trial of Suicide Gene Therapy and Prostate Cancer

    Not yet reported Henry Ford Health System 44 participants Est. completion 2013-09 2 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00730769

    Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients

    Not yet reported Salvador Gil-Vernet 21 participants Est. completion 2008-07 1 site Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Status unknown NCT NCT00828503

    Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients

    Not yet reported Marcus Saemann 40 participants Est. completion 2014-06 1 site
    Other conditions: Cytomegalovirus Disease
    View official trial listing →
  • Terminated NCT NCT00917826

    Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

    Not yet reported HemaQuest Pharmaceuticals Inc. 1 participants 1 site Stand-alone
    Other conditions: EBV Lymphomas, Lympho-proliferative Diseases
    View official trial listing →
  • Completed NCT NCT00947141

    Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)

    Not yet reported University College, London 165 participants Est. completion 2013-02 1 site Stand-alone
    Other conditions: Viraemia
    View official trial listing →
  • Status unknown NCT NCT00966836

    Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy

    Not yet reported University of Bologna 100 participants 1 site Stand-alone
    Other conditions: Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection
    View official trial listing →
  • Terminated NCT NCT00992732

    Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

    Not yet reported HemaQuest Pharmaceuticals Inc. 1 participants 8 sites Stand-alone
    Other conditions: Lymphoid Malignancies, Lymphoproliferative Disorders
    View official trial listing →
  • No Longer Available NCT NCT01049633

    B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

    National Institute of Allergy and Infectious Diseases (NIAID) 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01077908

    Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

    Not yet reported Cell Medica Ltd 89 participants Est. completion 2014-10 14 sites Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT01165580

    A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

    Not yet reported Hoffmann-La Roche 17 participants Est. completion 2013-09 19 sites Stand-alone
    Other conditions: Cytomegalovirus Infections, Heart Transplantation
    View official trial listing →
  • Terminated NCT NCT01185223

    Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

    Not yet reported Pierrel Research Europe GmbH 212 participants 17 sites
    Other conditions: Allogeneic Stem Cell Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT01199562

    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

    City of Hope Medical Center 153 participants Est. completion 2026-12-01 1 site
    Obstructive sleep apnea Other conditions: Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Cytomegalovirus Infection, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01220895

    Alternate Donor Study of Pre-Emptive Cellular Therapy

    Not yet reported Cell Medica Ltd 52 participants Est. completion 2014-01 9 sites Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT01255644

    Antiviral Treatment of Chronic Lymphocytic Leukemia

    Not yet reported Medical University of Vienna 20 participants Est. completion 2015-07 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01329185

    Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

    Not yet reported University of Minnesota 17 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: EBV Viremia, CMV Viremia
    View official trial listing →
  • Completed NCT NCT01335932

    Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

    Not yet reported Fred Hutchinson Cancer Center 160 participants Est. completion 2016-10-28 14 sites Stand-alone
    Other conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
    View official trial listing →
  • Completed NCT NCT01376804

    A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

    Not yet reported Hoffmann-La Roche 57 participants Est. completion 2013-05-31 25 sites Stand-alone
    Other conditions: Kidney Transplantation, Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT01441063

    Tocilizumab for KSHV-Associated Multicentric Castleman Disease

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2020-10-05 1 site Stand-alone
    Other conditions: Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
    View official trial listing →
  • Completed NCT NCT01446445

    Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.

    Not yet reported Nuria Lloberas 60 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Infection in Solid Organ Transplant Recipients
    View official trial listing →
  • Completed NCT NCT01503918

    Cytomegalovirus Control in Critical Care

    Not yet reported University Hospital Birmingham NHS Foundation Trust 124 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Critical Illness
    View official trial listing →
  • Completed NCT NCT01509404

    Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

    Not yet reported Medical University of South Carolina 40 participants Est. completion 2015-12 1 site
    Other conditions: Cytomegalovirus Disease
    View official trial listing →
  • Completed NCT NCT01552369

    CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 205 participants Est. completion 2018-06-22 6 sites Stand-alone
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT01611974

    Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

    Not yet reported Shire 120 participants Est. completion 2014-12-05 32 sites
    Other conditions: Cytomegalovirus (CMV)
    View official trial listing →
  • Completed NCT NCT01649869

    Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 54 participants Est. completion 2019-12-24 18 sites
    Other conditions: Cytomegalovirus Infection
    View official trial listing →
  • Terminated NCT NCT01655212

    Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

    Not yet reported Dr. Ann C.T.M. Vossen 2 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Congenital Cytomegalovirus Infection, Sensorineural Hearing Loss
    View official trial listing →
  • Completed NCT NCT01663740

    A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

    Not yet reported Hoffmann-La Roche 59 participants Est. completion 2016-12-30 19 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT01972035

    ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

    Not yet reported University of Minnesota 137 participants Est. completion 2021-02-28 1 site
    Other conditions: Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT02005822

    Congenital Cytomegalovirus: Efficacy of Antiviral Treatment

    Not yet reported Dr. Ann C.T.M. Vossen 37 participants Est. completion 2018-05-17 1 site Stand-alone
    Other conditions: Congenital Cytomegalovirus Infection, Sensorineural Hearing Loss
    View official trial listing →
  • Completed NCT NCT02062294

    An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients

    Hoffmann-La Roche 14 participants Est. completion 2011-09-30 3 sites
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Terminated NCT NCT02188719

    Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 15 participants Est. completion 2019-06-18 3 sites Stand-alone
    Other conditions: Liver Transplantation
    View official trial listing →
  • Completed NCT NCT02296723

    Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition

    Not yet reported Dr. Reddy's Laboratories Limited 66 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02297854

    Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition

    Not yet reported Dr. Reddy's Laboratories Limited 83 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02370758

    Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients

    Not yet reported University Health Network, Toronto 32 participants Est. completion 2017-06-16 1 site
    Other conditions: Cytomegalovirus Viraemia
    View official trial listing →
  • Withdrawn NCT NCT02409147

    Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center

    Not yet reported University of Nebraska Est. completion 2018-07-24 Stand-alone
    Other conditions: Uterus Transplant
    View official trial listing →
  • Terminated NCT NCT02439957

    A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

    Not yet reported Jazz Pharmaceuticals 6 participants Est. completion 2016-07-31 3 sites
    Other conditions: Cytomegalovirus Disease, Kidney Transplant Infection
    View official trial listing →
  • Terminated NCT NCT02439970

    A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

    Not yet reported Jazz Pharmaceuticals 5 participants Est. completion 2016-01-30 3 sites
    Other conditions: Cytomegalovirus Disease
    View official trial listing →
  • Completed NCT NCT02503982

    Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients

    Not yet reported Rabin Medical Center 13 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Infection in Solid Organ Transplant Recipients
    View official trial listing →
  • Completed NCT NCT02538172

    Cell-mediated Immunity for Prevention of CMV Disease

    Not yet reported University of Lausanne Hospitals 195 participants Est. completion 2021-01 5 sites Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Terminated NCT NCT02606266

    Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

    Not yet reported, Not yet reported Assistance Publique - Hôpitaux de Paris 1 participants Est. completion 2018-12-11 1 site Stand-alone
    Other conditions: Congenital Cytomegalovirus (CMV)
    View official trial listing →
  • Status unknown NCT NCT02761291

    Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

    Not yet reported Chang Gung Memorial Hospital 18 participants 1 site Stand-alone
    Other conditions: Nasopharyngeal Carcinoma
    View official trial listing →
  • Completed NCT NCT02871401

    A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

    Not yet reported Vanderbilt University Medical Center 31 participants Est. completion 2020-01-31 1 site Stand-alone
    Other conditions: Idiopathic Pulmonary Fibrosis
    View official trial listing →
  • Completed NCT NCT02927067

    A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

    Not yet reported Shire 553 participants Est. completion 2022-07-01 129 sites Stand-alone
    Other conditions: Cytomegalovirus (CMV)
    View official trial listing →
  • Completed NCT NCT02931539

    Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

    Not yet reported Shire 352 participants Est. completion 2020-08-17 134 sites
    Other conditions: Cytomegalovirus (CMV)
    View official trial listing →
  • Status unknown NCT NCT02973464

    The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population

    First Affiliated Hospital Xi'an Jiaotong University 450 participants Est. completion 2019-12 1 site
    Other conditions: Renal Transplant Recipients
    View official trial listing →
  • Withdrawn NCT NCT03029871

    Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

    Not yet reported Benjamin Movsas, M.D. Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer Stage I
    View official trial listing →
  • Terminated NCT NCT03107871

    Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

    Not yet reported Albert Park 10 participants Est. completion 2022-08-31 30 sites Stand-alone
    Other conditions: Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
    View official trial listing →
  • Completed NCT NCT03123627

    Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.

    Not yet reported Maimónides Biomedical Research Institute of Córdoba 150 participants Est. completion 2019-10-21 1 site
    Other conditions: Kidney Transplant Infection
    View official trial listing →
  • Completed NCT NCT03296553

    Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

    Not yet reported National Institute of Cancerología 40 participants Est. completion 2019-08-26 1 site Stand-alone
    Other conditions: Kaposi Sarcoma, Human Immunodeficiency Virus, Immune Reconstitution Syndrome
    View official trial listing →
  • Terminated NCT NCT03301415

    Asymptomatic Congenital CMV Treatment

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 7 participants Est. completion 2020-11-05 9 sites Stand-alone
    Other conditions: Congenital Cytomegalovirus Infection
    View official trial listing →
  • Completed NCT NCT03339661

    Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.

    Not yet reported University Hospital, Bordeaux 38 participants Est. completion 2020-11-23 2 sites Stand-alone
    Other conditions: Kidney Transplant Infection
    View official trial listing →
  • Completed NCT NCT03397706

    Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

    Not yet reported, Not yet reported Viracta Therapeutics, Inc. 64 participants Est. completion 2023-05-04 28 sites Stand-alone
    Other conditions: Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
    View official trial listing →
  • Completed NCT NCT03443869

    Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

    Not yet reported Merck Sharp & Dohme LLC 601 participants Est. completion 2022-04-05 94 sites Stand-alone
    Other conditions: CMV Disease
    View official trial listing →
  • Terminated NCT NCT03586284

    Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

    Not yet reported, Not yet reported University of California, San Francisco 51 participants Est. completion 2024-11-13 4 sites
    Other conditions: Cytomegalovirus Anterior Uveitis
    View official trial listing →
  • Completed NCT NCT03631316

    Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir

    Not yet reported Luis Eduardo Morales Buenrostro 8 participants Est. completion 2018-11-01 1 site Stand-alone
    Other conditions: Kidney Transplantation, Cytomegalovirus Infections, Pharmacokinetics, Therapeutic Equivalency
    View official trial listing →
  • Status unknown NCT NCT03698435

    (Val)Ganciclovir TDM in Transplant Recipients

    University Medical Center Groningen 100 participants Est. completion 2019-12-31 1 site
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT03699254

    Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.

    Not yet reported Maimónides Biomedical Research Institute of Córdoba 150 participants Est. completion 2023-05-29 7 sites Stand-alone
    Other conditions: Transplantation Infection, Cytomegalovirus Infections
    View official trial listing →
  • Completed NCT NCT03915366

    Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

    Not yet reported, Not yet reported Hospital Universitario 12 de Octubre 563 participants Est. completion 2025-01-31 13 sites Stand-alone
    Other conditions: Pneumonia, HIV/AIDS, Tuberculosis, Cytomegalovirus Infections
    View official trial listing →
  • Terminated NCT NCT04064697

    Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy

    Not yet reported Centre Hospitalier Universitaire de Saint Etienne 6 participants Est. completion 2024-02-08 8 sites Stand-alone
    Other conditions: Ulcerative Colitis, Unspecified
    View official trial listing →
  • Active, not recruiting NCT NCT04116411

    A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients

    Not yet reported Cecilia Soderberg-Naucler 220 participants Est. completion 2027-09-16 3 sites
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Status unknown NCT NCT04278547

    Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response

    Not yet reported Hospital Universitari de Bellvitge 188 participants Est. completion 2023-03-25 1 site Stand-alone
    Other conditions: Heart Transplant Infection, CMV Infection
    View official trial listing →
  • Completed NCT NCT04313868

    GEN2 Directed Cancer Immunotherapy Trial

    Not yet reported GenVivo, Inc. 61 participants Est. completion 2023-12-12 4 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT04724447

    ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

    Not yet reported, Not yet reported Laureate Institute for Brain Research, Inc. 20 participants Est. completion 2026-04-01 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Terminated NCT NCT05011058

    An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

    Not yet reported Viracta Therapeutics, Inc. 102 participants Est. completion 2025-01-31 62 sites Stand-alone
    Other conditions: Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
    View official trial listing →
  • Completed NCT NCT05041426

    Letermovir for CMV Prevention After Lung Transplantation

    Not yet reported Fernanda P Silveira, MD, MS 15 participants Est. completion 2025-03-03 1 site
    Other conditions: Lung Transplant, CMV
    View official trial listing →
  • Terminated NCT NCT05166577

    Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

    Not yet reported Viracta Therapeutics, Inc. 26 participants Est. completion 2025-01-10 13 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV Related Carcinoma, EBV-Related Sarcoma
    View official trial listing →
  • Completed NCT NCT05238220

    Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

    Piedmont Healthcare 37 participants Est. completion 2022-06-30 1 site
    Other conditions: Kidney Transplant; Complications
    View official trial listing →
  • Withdrawn NCT NCT05431244

    Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)

    Not yet reported Samsung Medical Center Est. completion 2024-07-01 1 site
    Other conditions: Gastric Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05595473

    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

    Not yet reported, Not yet reported Rznomics, Inc. 42 participants Est. completion 2029-05 5 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT06001320

    De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

    Not yet reported Virginia Commonwealth University 30 participants Est. completion 2026-09-01 1 site Stand-alone
    Other conditions: Kidney Transplant; Complications, CMV
    View official trial listing →
  • Completed NCT NCT06034925

    Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

    Not yet reported Medical University of South Carolina 70 participants Est. completion 2025-08-30 1 site
    Other conditions: Transplant Complication, CMV
    View official trial listing →
  • Not yet recruiting NCT NCT06057194

    Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

    Not yet reported Maimónides Biomedical Research Institute of Córdoba 90 participants Est. completion 2027-04 1 site
    Other conditions: Infections, Cytomegalovirus
    View official trial listing →
  • Completed NCT NCT06118515

    A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 3 participants Est. completion 2026-05-04 3 sites Stand-alone
    Other conditions: Congenital Cytomegalovirus Infection
    View official trial listing →
  • Terminated NCT NCT06302140

    A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

    Not yet reported Viracta Therapeutics, Inc. 8 participants Est. completion 2025-01-15 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Status unknown NCT NCT06339892

    HCMV Breakthrough Infections During Letermovir Prophylaxis

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 140 participants Est. completion 2026-03 8 sites Stand-alone
    Other conditions: Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
    View official trial listing →
  • Terminated NCT NCT06391918

    Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

    Not yet reported GenVivo, Inc. 37 participants Est. completion 2026-03-01 7 sites
    Other conditions: Solid Tumor, Adult
    View official trial listing →
  • Completed NCT NCT06439342

    A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

    Not yet reported Takeda 20 participants Est. completion 2026-07-22 11 sites
    Other conditions: Cytomegalovirus (CMV)
    View official trial listing →
  • Available NCT NCT06676891

    Expanded Access Program for GBM Subjects

    Rznomics, Inc. 1 site
    Other conditions: Glioblastoma
    View official trial listing →
  • Enrolling by invitation NCT NCT07009548

    CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

    Not yet reported Fernanda P Silveira, MD, MS 45 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Cytomegalovirus (CMV) Infection
    View official trial listing →
  • Not yet recruiting NCT NCT07138989

    EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

    Not yet reported Sun Yat-sen University 10 participants Est. completion 2031-08-18 1 site Stand-alone
    Other conditions: Nasopharyngeal Cancinoma (NPC)
    View official trial listing →
  • Not yet recruiting NCT NCT07203664

    Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.

    Not yet reported Hospital Universitario La Paz 30 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients
    View official trial listing →
  • Not yet recruiting NCT NCT07379203

    ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse

    Not yet reported Wits Health Consortium (Pty) Ltd 130 participants Est. completion 2027-06-30 Stand-alone
    Other conditions: Cytomegalovirus (CMV) Infection
    View official trial listing →
  • Active, not recruiting NCT NCT07430683

    Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients

    Not yet reported University of Guadalajara 68 participants Est. completion 2026-07-31 1 site Stand-alone
    Other conditions: Cytomegalovirus Infections
    View official trial listing →
  • Not yet recruiting NCT NCT07450365

    Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection

    Not yet reported Hu Bofei 150 participants Est. completion 2028-12-31 Stand-alone
    Other conditions: Congenital CMV Infection
    View official trial listing →
  • Not yet recruiting NCT NCT07513623

    Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

    Not yet reported University of California, San Francisco 117 participants Est. completion 2032-10-31 6 sites
    Other conditions: Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
    View official trial listing →
  • Not yet recruiting NCT NCT07571135

    Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

    Not yet reported Elisabeth Kincaide 300 participants Est. completion 2028-11 1 site
    Other conditions: CMV Infection, CMV, CMV Viremia, CMV Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Valganciclovir Hydrochloride, Valganciclovir hydrochloride for Oral, Valganciclovir, Valcyte, VGCV

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.